Pioglitazone increases circulating microRNA-24 with decrease in coronary neointimal hyperplasia in type 2 diabetic patients: Optical coherence tomography analysis

Circulation Journal

Volumn 79, Issue 4, 2015, Pages 880-888

  Hong, Soon Jun ^a   Choi, Seung Cheol ^a   Cho, Jae Young ^a   Joo, Hyung Joon ^a   Park, Jae Hyoung ^a   Yu, Cheol Woong ^a   Lim, Do Sun ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Diabetes; Endothelial function; MicroRNA; Pioglitazone

Indexed keywords

ACETYLSALICYLIC ACID; ADIPONECTIN; ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EVEROLIMUS; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MICRORNA; MICRORNA 126; MICRORNA 145; MICRORNA 17; MICRORNA 24; MICRORNA 92A; NICORANDIL; PIOGLITAZONE; PLACEBO; RETINOL BINDING PROTEIN 4; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; MIRN24 MICRORNA, HUMAN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD FLOW VELOCITY; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY NEOINTIMAL HYPERPLASIA; CORONARY STENTING; DIABETIC PATIENT; DIAGNOSTIC TEST ACCURACY STUDY; DOPPLER ECHOCARDIOGRAPHY; DRUG ELUTING STENT; ENDOTHELIAL DYSFUNCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERPLASIA; IMMUNORADIOMETRIC ASSAY; INSULIN RESISTANCE; MALE; NEOVASCULARIZATION (PATHOLOGY); NON INSULIN DEPENDENT DIABETES MELLITUS; OPTICAL COHERENCE TOMOGRAPHY; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SYSTOLIC BLOOD PRESSURE; BLOOD; CLINICAL TRIAL; CORONARY BLOOD VESSEL; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; NEOINTIMA; PATHOLOGY;

AGED; CORONARY VESSELS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; HYPERPLASIA; HYPOGLYCEMIC AGENTS; MALE; MICRORNAS; MIDDLE AGED; NEOINTIMA; THIAZOLIDINEDIONES; TOMOGRAPHY, OPTICAL COHERENCE;

EID: 84925660941     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-14-0964     Document Type: Article

References (35)

1. Libby P, Plutzky J. Inflammation in diabetes mellitus: Role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator- activated receptor-gamma agonists. Am J Cardiol 2007; 99: 27B-40B.
2. Choi KY, Kim DB, Kim MJ, Kwon BJ, Chang SY, Jang SW, et al. Higher plasma thrombospondin-1 levels in patients with coronary artery disease and diabetes mellitus. Korean Circ J 2012; 42: 100-106.
3. Iwasaki M, Otake H, Shinke T, Nakagawa M, Hariki H, Osue T, et al. Vascular responses in patients with and without diabetes mellitus after everolimus-eluting stent implantation: Optical coherence tomography study. Circ J 2014; 78: 2188-2196.
4. Hong SJ, Kim MH, Ahn TH, Ahn YK, Bae JH, Shim WJ, et al. Multiple predictors of coronary restenosis after drug-eluting stent implantation in patients with diabetes. Heart 2006; 92: 1119-1124.
5. Hong SJ, Kim MH, Cha KS, Park HS, Chae SC, Hur SH, et al. Comparison of three-year clinical outcomes between sirolimus-versus paclitaxel-eluting stents in diabetic patients: Prospective randomized multicenter trial. Catheter Cardiovasc Interv 2010; 76: 924-933.
6. Meigs JB, Hu FB, Rifai N, Manson JE. Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA 2004; 291: 1978-1986.
7. Akcakoyun M, Kargin R, Tanalp AC, Pala S, Ozveren O, Akcay M, et al. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events and restenosis in patients undergoing coronary stent implantation: A prospective study. Coron Artery Dis 2008; 19: 337-343.
8. Gilbert RE. Endothelial loss and repair in the vascular complications of diabetes: Pathogenetic mechanisms and therapeutic implications. Circ J 2013; 77: 849-856.
9. Hong SJ, Kim ST, Kim TJ, Kim EO, Ahn CM, Park JH, et al. Cellular and molecular changes associated with inhibitory effect of pioglitazone on neointimal growth in patients with type 2 diabetes after zotarolimus-eluting stent implantation. Arterioscler Thromb Vasc Biol 2010; 30: 2655-2665.
10. Fichtlscherer S, Zeiher AM, Dimmeler S. Circulating microRNAs: Biomarkers or mediators of cardiovascular diseases? Arterioscler Thromb Vasc Biol 2011; 31: 2383-2390.
11. De Rosa S, Curcio A, Indolfi C. Emerging role of microRNAs in cardiovascular diseases. Circ J 2014; 78: 567-575.
12. Cheng Y, Liu X, Yang J, Lin Y, Xu DZ, Lu Q, et al. MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation. Circ Res 2009; 105: 158-166.
13. Doebele C, Bonauer A, Fischer A, Scholz A, Reiss Y, Urbich C, et al. Members of the microRNA-17-92 cluster exhibit a cell-intrinsic antiangiogenic function in endothelial cells. Blood 2010; 115: 4944-4950.
14. Zhou J, Li YS, Nguyen P, Wang KC, Weiss A, Kuo YC, et al. Regulation of vascular smooth muscle cell turnover by endothelial cellsecreted microRNA-126: Role of shear stress. Circ Res 2013; 113: 40-51.
15. Treguer K, Heinrich EM, Ohtani K, Bonauer A, Dimmeler S. Role of the microRNA-17-92 cluster in the endothelial differentiation of stem cells. J Vasc Res 2012; 49: 447-460.
16. Boon RA, Dimmeler S. MicroRNA-126 in Atherosclerosis. Arterioscler Thromb Vasc Biol 2014; 34: e15-e16, doi:10.1161/ATVBAHA.114.303572.
17. Schober A, Nazari-Jahantigh M, Wei Y, Bidzhekov K, Gremse F, Grommes J, et al. MicroRNA-126-5p promotes endothelial proliferation and limits atherosclerosis by suppressing Dlk 1. Nat Med 2014; 20: 368-376.
18. Wang J, Huang W, Xu R, Nie Y, Cao X, Meng J, et al. MicroRNA-24 regulates cardiac fibrosis after myocardial infarction. J Cell Mol Med 2012; 16: 2150-2160.
19. Di Gregoli K, Jenkins N, Salter R, White S, Newby AC, Johnson JL. MicroRNA-24 regulates macrophage behavior and retards atherosclerosis. Arterioscler Thromb Vasc Biol 2014; 34: 1990-2000.
20. Hong SJ, Choi SC, Ahn CM, Park JH, Kim JS, Lim DS. Telmisartan reduces neointima volume and pulse wave velocity 8 months after zotarolimus-eluting stent implantation in hypertensive type 2 diabetic patients. Heart 2011; 97: 1425-1432.
21. Advani A, Connelly KA, Advani SL, Thai K, Zhang Y, Kelly DJ, et al. Role of the eNOS-NO system in regulating the antiproteinuric effects of VEGF receptor 2 inhibition in diabetes. Biomed Res Int 2013; 2013: 201475, doi:10.1155/2013/201475.
22. Kim YS, Kang HJ, Hong MH, Kang WS, Choe N, Kook H, et al. Angiopoietin-like 4 is involved in the poor angiogenic potential of high glucose-insulted bone marrow stem cells. Korean Circ J 2014; 44: 177-183.
23. Li DF, Tian J, Guo X, Huang LM, Xu Y, Wang CC, et al. Induction of microRNA-24 by HIF-1 protects against ischemic injury in rat cardiomyocytes. Physiol Res 2012; 61: 555-565.
24. Takayama K, Sukhova GK, Chin MT, Libby P. A novel prostaglandin E receptor 4-associated protein participates in antiinflammatory signaling. Circ Res 2006; 98: 499-504.
25. Cheang WS, Fang X, Tian XY. Pleiotropic effects of peroxisome proliferator-activated receptor gamma and delta in vascular diseases. Circ J 2013; 77: 2664-2671.
26. Mizoguchi M, Tahara N, Tahara A, Nitta Y, Kodama N, Oba T, et al. Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes: A prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta. JACC Cardiovasc Imaging 2011; 4: 1110-1118.
27. Hong SJ, Shim WJ, Choi JI, Joo HJ, Shin SY, Park SM, et al. Comparison of effects of telmisartan and valsartan on late lumen loss and inflammatory markers after sirolimus-eluting stent implantation in hypertensive patients. Am J Cardiol 2007; 100: 1625-1629.
28. Dohi T, Miyauchi K, Iesaki T, Tsuruta R, Tsuboi S, Ogita M, et al. Candesartan with pioglitazone protects against endothelial dysfunction and inflammatory responses in porcine coronary arteries implanted with sirolimus-eluting stents. Circ J 2011; 75: 1098-1106.
29. Nitta Y, Tahara N, Tahara A, Honda A, Kodama N, Mizoguchi M, et al. Pioglitazone decreases coronary artery inflammation in impaired glucose tolerance and diabetes mellitus: Evaluation by FDG-PET/CT imaging. JACC Cardiovasc Imaging 2013; 6: 1172-1182.
30. Saremi A, Schwenke DC, Buchanan TA, Hodis HN, Mack WJ, Banerji M, et al. Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors. Arterioscler Thromb Vasc Biol 2013; 33: 393-399.
31. Gilbert RE. Sodium-glucose linked transporter-2 inhibitors: Potential for renoprotection beyond blood glucose lowering? Kidney Int 2014; 86: 693-700.
32. Hong SJ, Seo HS, Rha SW, Oh DJ, Kwon JA, Lee KN, et al. Decrease in plasma adiponectin concentrations in patients with variant angina pectoris. Circ J 2006; 70: 414-418.
33. Mirza S, Hossain M, Mathews C, Martinez P, Pino P, Gay JL, et al. Type 2-diabetes is associated with elevated levels of TNF-alpha, IL-6 and adiponectin and low levels of leptin in a population of Mexican Americans: A cross-sectional study. Cytokine 2012; 57: 136-142.
34. Calabro P, Willerson JT, Yeh ET. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation 2003; 108: 1930-1932.
35. Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005; 436: 356-362.